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The Farnesyl Transferase Inhibitor Lonafarnib Inhibits
mTOR Signaling and Enforces Sorafenib-Induced
Apoptosis in Melanoma Cells
Heike Niessner1, Daniela Beck1, Tobias Sinnberg1, Konstantinos Lasithiotakis1, Evelyn Maczey1,
Jeannette Gogel1, Sascha Venturelli2, Alexander Berger2, Mario Mauthe3, Mahmoud Toulany4,
Keith Flaherty5, Martin Schaller1, Dirk Schadendorf6, Tassula Proikas-Cezanne3, Birgit Schittek1,
Claus Garbe1, Dagmar Kulms7 and Friedegund Meier1
Farnesyl transferase inhibitors (FTIs) inhibit the farnesylation of proteins, including RAS and RHEB (Ras homolog
enriched in brain). RAS signals to the RAF–MEK–ERK (MAPK) and PI3K–AKT–mTOR (AKT) signaling pathways, which
have a major role in melanoma progression. RHEB positively regulates mammalian target of rapamycin (mTOR).
We investigated the effects of the FTI lonafarnib alone and in combination with MAPK (mitogen-activated
protein kinase) or AKT (acutely transforming retrovirus AKT8 in rodent T-cell lymphoma) pathway inhibitors on
proliferation, survival, and invasive tumor growth of melanoma cells. Lonafarnib alone did not sufficiently
inhibit melanoma cell growth. Combinations of lonafarnib with AKT pathway inhibitors did not significantly
increase melanoma cell growth inhibition. In contrast, combinations of lonafarnib with MAPK pathway
inhibitors yielded additional growth-inhibiting effects. In particular, the combination of the FTI lonafarnib
with the pan-RAF inhibitor sorafenib synergistically inhibited melanoma cell growth, significantly enhanced
sorafenib-induced apoptosis, and completely suppressed invasive tumor growth in monolayer and organotypic
cultures, respectively. Apoptosis induction was associated with upregulation of the endoplasmic reticulum
stress-related transcription factors p8 and CHOP (CAAT/enhancer binding protein (C/EBP) homologous
protein), and downregulation of the antiapoptotic Bcl-2 (B-cell lymphoma-2) family protein Mcl-1(myeloid
cell leukemia 1). Lonafarnib did not affect MAPK and AKT but did affect mTOR signaling. Together, these
findings suggest that the FTI lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in
melanoma cells and may therefore represent an effective alternative for melanoma treatment.
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INTRODUCTION
The prognosis of patients with metastatic melanoma is poor,
with a 5-year survival probability of o5%, reflecting the
failure of chemotherapy or/and immunotherapy regimens
(Flaherty, 2006). We have learned from recent research that
the RAF–MEK–ERK (MAPK) and the PI3K–AKT–mTOR (AKT)
signaling pathways have a major role in melanoma progres-
sion (Davies et al., 2002; Satyamoorthy et al., 2003; Dai
et al., 2005; Meier et al., 2005). Thus, the MAPK (mitogen-
activated protein kinase) or/and AKT (acutely transforming
retrovirus AKT8 in rodent T-cell lymphoma) signal transduc-
tion pathways may be promising targets for effective
melanoma treatment.
The pan-RAF inhibitor sorafenib inhibits the MAPK
signaling pathway both in vitro and in vivo (Karasarides
et al., 2004). However, a phase II study revealed that
sorafenib is not effective in patients with metastatic melano-
ma (Eisen et al., 2006). Analogous, the mammalian target of
rapamycin (mTOR) inhibitors CCI-779 and RAD-001 inhibit
their target in vivo, but they have been proved ineffective in
melanoma patients (Margolin et al., 2005; Rao et al., 2007).
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Interestingly, recent in vitro studies showed that metastatic
melanoma cell lines may be resistant to both MAPK and
AKT pathway inhibitors, whereas the combination of MAPK
with AKT pathway inhibitors suppresses the growth and
invasion of metastatic melanoma cells (Smalley et al., 2006;
Meier et al., 2007). Farnesyl transferase inhibitors (FTIs)
inhibit the post-translational farnesylation of a number of
target proteins, including RAS and RHEB (Ras homolog
enriched in brain), and may alter their signaling function
(Sebti and Der, 2003). RAS signals to the RAF–MEK–ERK
and PI3K–AKT–mTOR signaling pathways. RHEB stimulates
mTOR activity in a guanosine triphosphate-dependent
manner.
As FTIs may be capable of inhibiting both the RAF–MEK–ERK
and PI3K–AKT–mTOR signaling pathways, we investigated the
effects of the FTI lonafarnib alone and in combination with
MAPK or AKT pathway inhibitors on proliferation, survival, and
invasive tumor growth of melanoma cells.
RESULTS
Lonafarnib inhibits farnesyl transferase in melanoma cells
To assess farnesyl transferase (FT) inhibition by lonafarnib
in melanoma cells, we investigated mobility shifts of the
nuclear chaperone HDJ2, a highly expressed FT target protein
(Smalley and Eisen, 2003). In the presence of increasing
concentrations of lonafarnib, HDJ2 migrated to a higher
apparent molecular weight, consistent with FT inhibition in
all melanoma cell lines tested (Figure 1).
A combination of lonafarnib and sorafenib potently inhibits
melanoma cell growth
Using a panel of four human metastatic melanoma cell
lines (NRASQ61R mutation: BLM, MV3; NRASWT/BRAFWT:
MEWO; BRAFV600E mutation: SKMEL19), the effects of the
FTI lonafarnib alone and in combination with AKT pathway
inhibitors (phosphatidylinositol 3-kinase (PI3K): LY294002,
wortmannin; mTOR: rapamycin) or MAPK pathway inhibitors
(RAF: sorafenib, MAPK/ERK kinase (MEK): U0126, PD98059)
on melanoma cell viability in monolayer culture were
determined by a fluorimetric assay using 4-methylumbelliferyl
heptanoate. The doses needed to specifically inhibit the
selective pathways have been verified before using the same
cell lines (Smalley et al., 2006; Lasithiotakis et al., 2008).
Treatment of melanoma cells with the FTI lonafarnib alone
did not sufficiently inhibit melanoma cell growth, with
corresponding growth inhibition rates not exceeding 39%
in all cell lines tested (Supplementary Figure S1A-B online).
Combinations of lonafarnib with AKT pathway inhibitors
such as the PI3K inhibitor LY294002 did not significantly
increase growth inhibition of most melanoma cell lines tested
compared with monotreatment with AKT pathway inhibitors
(Supplementary Figure S1A online). In contrast, combination
treatment of melanoma cells with lonafanib and MAPK
pathway inhibitors such as the MEK inhibitor U0126 yielded
additional growth-inhibiting effects in most melanoma cell
lines tested compared with monotreatment (Supplementary
Figure S1B online). In particular, the combination of the FTI
lonafarnib with the pan-RAF inhibitor sorafenib significantly
enhanced growth inhibition of all melanoma cell lines tested
compared with lonafarnib or sorafenib alone (Figure 2a).
Absolute enhancement of growth inhibition rates ranged from
53% (MEWO) to 90% (MV3).
We also investigated the effects of lonafarnib or/and
sorafenib on the growth of melanoma cells directly isolated
from excised skin metastases of five patients. Lonafarnib
combined with sorafenib significantly increased growth
inhibition compared with lonafarnib or sorafenib alone, with
growth inhibition rates up to 60.0% (Figure 2b).
To investigate the time dependency of cell death
processes, a real-time cell proliferation assay was performed
(Figure 2c). Combination treatment of metastatic melanoma
cells with lonafarnib and sorafenib significantly reduced the
percentage of detectable cells compared with monotreat-
ment. After 48 and 72 hours of combination treatment, only
50 and 30% of cells, compared with the beginning, were
detectable, respectively. For the purpose of comparison, we
also studied the effects of combination treatment with
sorafenib and the mTOR inhibitor rapamycin. Interestingly,
after 472 hours of treatment, sorafenib and lonafarnib
significantly reduced the percentage of viable melanoma
cells compared with sorafenib and rapamycin.
A response surface analysis (Tallarida, 2000) illustrated
(Figure 2d) that the effects of combination treatment of
melanoma cells with lonafarnib and sorafenib are positioned
above the surface of additivity, i.e., are superadditive or
synergistic.
Of note, the growth-inhibitory effects of lonafarnib and
sorafenib did not appear to depend on the BRAF (V-raf
murine sarcoma viral oncogene homolog B1) or NRAS
(neuroblastoma RAS viral (V-ras) oncogene homolog) muta-
tion status. For example, lonafarnib and sorafenib induced
similar absolute enhancement of growth inhibition rates in
SKMel19 melanoma cells with BRAFV600E mutation and
MV3 melanoma cells with NRASQ61R mutation (Figure 2a).
In contrast, the BRAFV600E kinase inhibitor PLX4032
significantly inhibited growth exclusively in the BRAFV600E
mutated melanoma cell line SKMel19 (Figure 2e).
Lona : – + ++
BLM
HDJ2
+++
MV3
MEWO
SKMel19
Figure 1. Lonafarnib inhibits farnesylation of the farnesyl transferase target
HDJ2. Melanoma cells (BLM, MV3, MEWO, and SKMel19) were incubated
with increasing concentrations of lonafarnib (0.1, 1, and 5 mM) for 24 hours,
followed by western blotting with anti-HDJ2 to detect the farnesylated
(faster migrating band) and unfarnesylated (slower migrating band) forms
of this farnesyl transferase target.
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Figure 2. Lonafarnib and sorafenib synergistically inhibit melanoma cell growth. Growth assay (4-methylumbelliferyl heptanoate (MUH)) of melanoma cell
lines (BLM, MV3, MEWO, and SKMel19) (a) and of melanoma cells directly isolated from excised skin metastases (b) treated with lonafarnib (lona) or/and
sorafenib (sora) for 72 hours. The percentage of growth inhibition compared with DMSO-treated controls is shown on the y axis (*Po0.05). (c) Real-time
proliferation assay of melanoma cells (BLM) treated with DMSO as control (ctrl), lonafarnib or/and sorafenib, rapamycin (rapa) or/and sorafenib, and Triton
X-100 0.1% as positive control for cell death. (d) Response surface analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with lonafarnib and
sorafenib for 72 hours (þ superadditive effects). (e) Growth assay (MUH) of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with increasing
concentrations of PLX4032.
470 Journal of Investigative Dermatology (2011), Volume 131
H Niessner et al.
Lonafarnib and Sorafenib in Melanoma
Lonafarnib enforces sorafenib-induced apoptosis in melanoma
cells
To investigate whether lonafarnib and sorafenib alone or in
combination affect cell cycle progression or/and survival
of melanoma cells, melanoma cells were treated with
DMSO as control, lonafarnib, sorafenib, or a combination of
both inhibitors, and cell cycle analysis was performed by
flow cytometry (Figure 3a). Exposure of melanoma cells to
lonafarnib or sorafenib alone did not result in an appreciable
cell cycle arrest but increased the percentage of cells in the
sub-G1 (apoptotic) cell fraction ranging from 6% (BLM) to
18% (MV3) in lonafarnib-treated cells and from 15% (BLM) to
49% (SKMel19) in sorafenib-treated cells, respectively.
Strikingly, coexposure of melanoma cells to lonafarnib and
sorafenib significantly increased the sub-G1 fraction ranging
from 27% (BLM) to 75% (SKMEL19). Of relevance, treatment
of human fibroblasts with lonafarnib, sorafenib, or a
combination of both did not increase the sub-G1 fraction
(Figure 3b), indicating the combination treatment to be
selective for melanoma.
Electron microscopy of melanoma cells treated with
lonafarnib and sorafenib revealed a typical apoptotic
morphology including cell fragmentation (Figure 3c).
Lonafarnib combined with sorafenib downregulates the
antiapoptotic Bcl-2 family proteins Bcl-2, Bcl-xL, and Mcl-1
Recent studies suggest that apoptosis induced by sorafenib
involves downregulation of antiapoptotic Bcl-2 (B-cell
lymphoma-2) family proteins such as Bcl-2, Bcl-xL (Bcl-extra
large), and Mcl-1 (myeloid cell leukemia 1) (Rahmani et al.,
2005; Yu et al., 2005). Thus, the striking effects of coexpo-
sure of melanoma cells to lonafarnib and sorafenib were
examined in relation to the expression of Bcl-2, Bcl-xL,
and Mcl-1 by western blot analysis (Figure 3d). Lonafarnib
marginally affected expression levels of Bcl-2, Bcl-xL, and
Mcl-1. Sorafenib decreased expression of Bcl-2 in three out of
four cell lines, did not affect Bcl-xL expression and potently
suppressed Mcl-1 expression in three out of four cell lines
tested. Most importantly, co-administration of lonafarnib and
sorafenib significantly reduced Bcl-2, slightly affected Bcl-xL,
and completely abolished Mcl-1 in all melanoma cell lines
tested.
Lonafarnib combined with sorafenib abrogates invasive
melanoma growth in organotypic culture
To investigate whether the combination therapy also sup-
presses invasive tumor growth of melanoma cells in a
physiological context, BLM melanoma cells were seeded
onto human skin reconstructs and were treated with DMSO
as control, lonafarnib, or/and sorafenib for 14 days (Figure 4).
Control-treated melanoma cells exhibited vertical invasive
growth of tumor cell strands deep into the dermis. Sorafenib
and to a lesser degree lonafarnib diminished invasive
melanoma growth (Figure 4a). Intriguingly, co-administration
of lonafarnib with sorafenib completely suppressed invasive
tumor growth with very few rounded melanoma cells
left in the dermis (Figure 4a). Staining with the proliferation
marker Ki67 demonstrates that sorafenib and, to a lesser
degree, lonafarnib reduced the number of proliferating
melanoma cells, whereas the combination of sorafenib
with lonafarnib completely abolished proliferating
melanoma cells in the dermis of human skin reconstructs
(Figure 4b).
Lonafarnib does not inhibit MAPK and AKT signaling but mTOR
signaling
To investigate whether the FTI lonafarnib affects the
RAF–MEK–ERK and PI3K–AKT signaling pathways, melanoma
cells were treated with lonafarnib or/and sorafenib, and
phosphorylated extracellular signal-regulated kinase (ERK)
and AKT were determined by western blot analysis. As
expected, sorafenib decreased the phosphorylation of ERK
but not of AKT (Figure 5a). Interestingly, lonafarnib affected
the phosphorylation of neither ERK nor AKT (Figure 5a).
Correspondingly, a RAS activation assay revealed that there
was no difference in RAS activity between control and
lonafarnib-treated cells (Figure 5b). Interestingly, RAS activity
was not observed in the BRAFV600E mutated cell line
SKMel19.
To examine whether lonafarnib affects mTOR signaling,
melanoma cells were treated with lonafarnib and subjected
to western blot analysis for phosphorylated S6 kinase and
ribosomal S6 protein, the downstream targets of mTOR.
Interestingly, lonafarnib decreased phosphorylation of S6
kinase and ribosomal S6 protein (Figure 5c).
Lonafarnib enhances sorafenib-induced upregulation of the ER
stress-related transcription factors p8 and CHOP
In a previous study investigating the antitumoral action of
sorafenib and the mTOR inhibitor rapamycin in melanoma
cells, the endoplasmic reticulum (ER) stress-associated
gene p8 was strongly upregulated compared with control
melanoma cells (unpublished data, Daniela Beck, Friedegund
Meier). We therefore investigated whether p8 upregulation
may also be involved in apoptotic effects caused by
cotreatment with lonafarnib and sorafenib. Exposure of
melanoma cells to lonafarnib alone slightly affected mRNA
levels of p8, whereas administration of sorafenib increased
p8 mRNA levels (Figure 6a). Interestingly, the combination
of lonafarnib and sorafenib resulted in further upregulation of
p8 in most melanoma cell lines tested (Figure 6a), suggesting
that apoptosis induction by this drug combination is
associated with upregulation of the transcription factor p8
and ER stress. To consolidate this assumption, melanoma
cells were treated as above and subjected to real-time PCR
and western blot analysis for the transcription factor CHOP
(CAAT/enhancer binding protein (C/EBP) homologous pro-
tein), which is induced by ER stress and is involved in ER
stress-induced apoptosis. Intriguingly, sorafenib and even
more lonafarnib plus sorafenib increased CHOP mRNA and
protein levels in all four melanoma cell lines tested (Figure 6a
and b). Interestingly, when we treated melanoma cells with
the classical ER stress inducer thapsigargin, we found that
thapsigargin strongly inhibits growth, induces apoptosis, and
upregulates the transcription factor p8 in all four melanoma
cell lines tested (Figure 6c).
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DISCUSSION
As FTIs may be capable of inhibiting both the MAPK and AKT
pathways that drive melanoma progression, we investigated
the effects of the FTI lonafarnib alone and in combination
with MAPK or AKT pathway inhibitors on melanoma cell
growth, survival, and invasion.
The FTI lonafarnib did not inhibit phosphorylation of ERK
or AKT; i.e., lonafarnib did not appear to affect RAF–ME-
K–ERK and PI3K–AKT signaling. However, lonafarnib affected
mTOR signaling. FTIs were initially developed to target RAS
in cancer cells that signal to the RAF–MEK–ERK and PI3K–AKT
signaling pathways. RAS function depends on its association
with the plasma membrane. RAS membrane association is
facilitated by the covalent attachment of a farnesyl isoprenoid
lipid catalyzed by the enzyme farnesyl transferase. However,
the RAS proteins that are most frequently mutated in human
cancers (KRAS and NRAS) undergo alternative prenylation,
thus escaping FTI inhibition (Sebti and Der, 2003). However,
another candidate FTI target is RHEB (Sebti and Der, 2003).
RHEB is a small GTPase and activates mTOR by antagoni-
zing its endogenous inhibitor FKBP38 (Bai et al., 2007). RHEB
is highly expressed in some human cancers, including
melanoma, and affects apoptosis. FTI treatment inhibits
RHEB farnesylation and activity, mTOR signaling, and the
antiapoptotic action of RHEB (Basso et al., 2005). In sum-
mary, the RHEB GTPase is an oncogenic activity upstream of
mTOR and a direct therapeutic target of FTIs in cancer
(Mavrakis et al., 2008).
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Figure 3. Continued.
Figure 3. Lonafarnib potentiates sorafenib-induced apoptosis of melanoma cells. (a) Cell cycle distribution of melanoma cells (BLM, MV3, MEWO, and
SKMel19) and (b) human fibroblasts 48 hours after treatment with DMSO as control, lonafarnib, or/and sorafenib. (c) Electron microscopy of melanoma
cells (BLM) treated with DMSO as control and lonafarnib (lona) plus sorafenib (sora) for 24 hours. In the control cells, cell membrane, mitochondria, and nucleus
are intact (arrows). Treated cells are packed into membrane vesicles (arrows). Scale bar¼2 mm. (d) Western blot analysis of melanoma cells (BLM, MV3,
MEWO, and SKMel19) 24 hours after treatment with lonafarnib or/and sorafenib for B-cell lymphoma-2 (Bcl-2), Bcl-extra large (Bcl-xL), and myeloid cell
leukemia 1 (Mcl-1).
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Strikingly, the combination of the FTI lonafarnib inhibiting
mTOR and the pan-RAF inhibitor sorafenib potently inhibited
growth, induced apoptosis, and suppressed invasive tumor
growth of melanoma cells in monolayer and organotypic
cultures. These results are supported by previous experi-
mental studies showing that combined inhibition of RAF and
mTOR signaling by sorafenib and rapamycin inhibits
melanoma cell growth, survival, and invasion (Molhoek
et al., 2005; Lasithiotakis et al., 2008). These data provide
further support for the evolving concept that simultaneous
interruption of two relevant signaling pathways represents a
promising strategy to inhibit growth and induce apoptosis in
tumor cells. Interestingly, the FTI lonafarnib combined with
sorafenib appeared to be more potent than the mTOR
inhibitor rapamycin combined with sorafenib. One explana-
tion for this observation might be that lonafarnib inhibits the
farnesylation of several proteins critical to melanoma
progression, including RHEB and PRL-3 (phosphatase of
regenerating liver-3). RHEB activates not only mTOR but also
NOTCH in an mTOR-independent manner (Karbowniczek
et al., 2010). Activated NOTCH signaling has been shown to
exert an oncogenic effect on melanoma development and
progression (Liu et al., 2006). PRL-3 has been found to
facilitate metastasis in many cancer types, it is required for
B16F1 melanoma cell metastasis in vitro and in vivo, and
inhibition of its farnesylation has been proposed as a new
approach to cancer therapy (Song et al., 2009).
A recent phase I study showed that the BRAFV600E
kinase inhibitor PLX4032 achieved partial remissions in
9 out of 16 patients with BRAFV600E melanoma, whereas
none of the patients with non-BRAFV600E melanoma
experienced a clinical response (Chapman et al., 2009),
demonstrating that selective potent inhibition of a relevant
altered signal transduction molecule may be effective in
selected patients with metastatic melanoma. Consistent
with this observation, the BRAFV600E kinase inhibitor
PLX4032 significantly inhibited growth exclusively in
BRAFV600E mutated melanoma cells. Interestingly, growth
inhibitory and proapoptotic effects of the FTI lonafarnib
and the pan-RAF inhibitor sorafenib did not depend on
the BRAF and NRAS mutation status of the melanoma cell
lines tested, suggesting that patients with non-BRAFV600E
melanoma who do not respond to treatment with PLX4032
may benefit from combination treatment with sorafenib
and lonafarnib.
Interestingly, lonafarnib together with sorafenib abolished
Mcl-1. Mcl-1 is thought to protect cells from a variety of
proapoptotic stimuli that activate the mitochondrial apop-
totic pathway, and it has been implicated in resistance to
anticancer drugs (Craig, 2002). Indeed, data accumulate
suggesting that targeting Mcl-1 may be particularly effective
in sensitizing melanoma cells to anticancer agents (Hersey,
2006; Verhaegen et al., 2006). Interestingly, the pan-RAF
inhibitor sorafenib has been reported to affect Mcl-1 protein
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levels (Rahmani et al., 2005; Yu et al., 2005), and mTOR has
been demonstrated to promote survival through translational
control of Mcl-1 (Mills et al., 2008). Accordingly, both the
pan-RAF inhibitor sorafenib and the FTI lonafarnib inhibiting
mTOR activity contribute to downregulation of the Mcl-1
protein, which appears to be a crucial player in mediating
therapy resistance in melanoma.
Recent data suggest that both the pan-RAF inhibitor
sorafenib and the FTI lonafarnib induce ER stress-mediated
apoptosis (Rahmani et al., 2007; Sun et al., 2007). The
mechanisms by which these drugs initiate ER stress are
unclear. Interestingly, cannabinoids were shown to induce
apoptosis in human glioma cells via activation of ER stress
through upregulation of ER stress-related genes such as the
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transcription factors p8 and CHOP (Salazar et al., 2009).
Indeed, lonafarnib in combination with sorafenib induced
upregulation of p8 and CHOP, suggesting that this drug
combination induces apoptosis in melanoma cells via
activation of ER stress. Moreover, we showed that the classical
ER stress inducer thapsigargin also upregulates the transcrip-
tion factor p8 and induces marked growth inhibition and
apoptosis in melanoma cells. Taken together, the presented
data suggest that melanoma cells are sensitive to ER stress and
that ER stress-inducing agents may present a promising
therapeutic strategy for patients with metastatic melanoma.
In summary, our data indicate that the FTI lonafarnib
inhibits mTOR signaling and potentiates sorafenib-induced
apoptosis in melanoma cells. Lonafarnib and sorafenib may
exert apoptosis induction in melanoma cells, at least in part
through downregulation of the antiapoptotic Bcl-2 family
protein Mcl-1. Furthermore, our data suggest that sorafenib
and lonafarnib induce apoptosis via upregulation of the
transcription factors p8 and CHOP and activation of ER stress.
The mechanisms by which sorafenib and lonafarnib induce
ER stress-mediated apoptosis are currently unclear and
deserve further study to provide a basis for a more rational
integration of sorafenib and lonafarnib into combination
regimens and for development of new ER stress-inducing
anticancer drugs.
MATERIALS AND METHODS
Isolation and culture of human cells
The use of human skin tissues was approved by the medical ethical
committee of the University of Tuebingen and was performed in
accordance with the Declaration of Helsinki Principles.
Metastatic melanoma cell lines (NRASQ61R mutation: BLM,
MV3; NRASWT/BRAFWT: MEWO; BRAFV600E mutation: SKMEL19),
melanoma cells from excised skin metastases, keratinocytes, and
fibroblasts were isolated and cultured as described previously
(Mancianti et al., 1988; Meier et al., 2000; Lasithiotakis et al.,
2008).
Treatment of melanoma cells with signaling pathway inhibitors
The following signal transduction inhibitors were used: the pan-RAF
inhibitor sorafenib (Bayer Corporation, West Haven, CT), the MEK
inhibitors PD98059 and U0126 (Cell Signaling Technology, Beverly,
MA), the PI3K inhibitors LY294002 (Cell Signaling Technology), and
wortmannin (Sigma Aldrich Chemie GmbH, Steinheim, Germany),
the mTOR inhibitor rapamycin (Sigma Aldrich, Taufkirchen, Germany),
and the FTI lonafarnib (Essex Pharma GmbH, Muenchen, Germany). For
ER stress induction, thapsigargin (Sigma) was used. Inhibitors were
dissolved in DMSO and were added directly to the culture medium
of melanoma cells at the concentrations to be tested. Melanoma
cells incubated with culture medium or culture medium with DMSO
served as controls.
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Western blot analyses
Western Blot analysis was performed as described previously
(Sinnberg et al., 2009). The following primary antibodies were used:
anti-ERK, anti-phosho-ERK (Thr202/Tyr204), anti-AKT, anti-phospho-
AKT (Thr308), anti-phospho-p70S6K, anti-p70S6K, anti-phosphoS6
ribosomal protein, anti-S6 ribosomal protein, anti-Bcl-2, anti-Bcl-xL,
anti-Mcl-1, anti-CHOP, anti-beta-actin (Cell Signaling Technology),
and anti-HDJ2 (NeoMarkers, Fremont, CA).
Growth assay
The assay was performed as described previously (Zouboulis et al.,
1991; Sinnberg et al., 2009).
Real-time cell proliferation assay
BLM cells (2.5 103 cells per well) were seeded in 96-well plates
(E-Plate 96, Roche Applied Science, Mannheim, Germany). Electrical
impedance was recorded every 15minutes, and shown are 6-hour
intervals. Continuous measurement was performed over a period of
96hours using the xCELLigence system (Xing et al., 2005). Cell index
values and normalization were calculated using the RTCA Software
(Roche Applied Sciences, Mannheim, Germany) (1.0.0.0805). Data
were normalized to the time of treatment at 24hours of cell culture.
Each experiment was performed three times in triplicates. Shown is
one representative experiment.
Ras activation assay
The assay was performed as described previously (Toulany et al.,
2007) using a pan-Ras antibody (Cell Signaling Technology).
Cell cycle analysis
The assay was performed as described previously (Sinnberg et al.,
2009).
Organotypic culture of human skin and melanoma
Organotypic cultures of human skin and melanoma were done as
described previously (Meier et al., 2000). To test the efficacy of the
inhibitors alone or in combination against invasive melanoma growth,
BLM melanoma cells were seeded onto human dermal reconstructs
and treated with lonafarnib (3 and 5mM) or/and sorafenib (2 and 4mM)
beginning on day 4. BLM cells treated with culture medium or culture
medium with the addition of DMSO served as controls.
Quantitative real-time PCR
The real-time PCR analysis was performed as described previously
(Sinnberg et al., 2009) using the p8 forward 50-ATAGCCTGGCCC
ATTCCT-30 and reverse 50-GCAGCAGCTTCTCTCTTGGT-30 primers
to yield a 120-bp amplificon, the CHOP forward 50-GCGTCTAGA
TCATGCTTGGTGCAGATTC-30 and reverse 50-GCGTCTAGAATGG
CAGCTGAGTCATTGCC-30 primers to yield a 509-bp amplificon,
whereas actin forward 50-TTGTTACAGGAAGTCCCTTGCC-30
and reverse 50-ATGCTATCACCTCCCCTGTGTG-30 primers gave a
101-bp PCR product.
Transmission electron microscopy
Cells were washed, centrifuged, and the resulting pellets were fixed
for 24 hours in Karnovsky’s fixative. After centrifugation, the
sediment was embedded in 3% agarose at 37 1C and then cooled
on ice. Postfixation was based on 1.0% osmium tetroxide containing
1.5% K-ferrocyanide in Aquadest for 2 hours. After embedding in
glycide ether the blocks containing cells were cut using an ultra
microtome (Ultracut, Reichert, Vienna, Austria) and ultrathin
sections (30 nm) were examined using a Zeiss Libra120 transmission
electron microscope (Carl Zeiss, Oberkochen, Germany) operating
at 120 kV.
Data analysis
Statistical analyses were performed with a two-tailed unpaired t-test.
The P-values of 0.05 were considered statistically significant.
Response surface analysis of melanoma cells treated with lonafarnib
and sorafenib was performed as previously described (Tallarida,
2000). Briefly, the effects of drug combinations (z axis) were plotted
against the concentrations of the single drugs (x and y axes).
The surface representing additive effects was developed with the
dose-response data curve fitted to the hyperbolic equation:
Effect ¼ ðmaximal effectconcentrationÞ=
ðmaximal effectþ concentration of half maximal effectÞ
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